Evidence map›Paper›PMID 42493540›Full record

Articlenpj drug discovery2026

A novel small molecule remyelination therapy for multiple sclerosis.

Yan Yang, Brain Bai, Lars J S Knutsen, Richard J Hamlyn, Qiao-Ling Cui, Jack Antel, Wendy Macklin, Satish Medicetty, Bruce D Trapp

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yan YangDepartment of Neurosciences, Cleveland Clinic, Cleveland, OH, USA.
Brain BaiRenovo Neural, Cleveland, OH, USA.
Lars J S KnutsenDiscovery Pharma Consulting LLC, West Chester, PA, USA.
Richard J HamlynRH Pharma Consulting Ltd, Cambridge, UK.
Qiao-Ling CuiMontreal Neurological Institute, McGill University, Montreal, QC, Canada.
Jack AntelMontreal Neurological Institute, McGill University, Montreal, QC, Canada.
Wendy MacklinCell & Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Satish MedicettyCashel Neural LLC., Cleveland, OH, USA.
Bruce D TrappDepartment of Neurosciences, Cleveland Clinic, Cleveland, OH, USA. TRAPPB@ccf.org.

Funding

High content screening to identify therapeutics for multiple sclerosisR43NS076060 · NINDS · RENOVO NEURAL, INC. · PI BAI, CHUNYANG BRIAN · 2012 to 2013
$605k
NIH HHS R35NS09730NIH HHS R43NS076060NINDS NIH HHS R43 NS076060
6 · The paper itself

Abstract

We conducted a phenotypic screen of 20,000 central nervous system (CNS)-biased small molecules for their ability to stimulate differentiation of mouse oligodendrocyte progenitor cells (OPCs) into oligodendrocytes. We identified a lead hit (CN045) with an EC

Identifiers

PMID42493540
PMCPMC13396656

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.